These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10915071)

  • 21. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848
    [No Abstract]   [Full Text] [Related]  

  • 22. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
    Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.
    Holguín A; Dietrich U; Immelmann A; Soriano V
    Antivir Ther; 1998; 3(3):183-6. PubMed ID: 10682136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
    Krogstad P; Wiznia A; Luzuriaga K; Dankner W; Nielsen K; Gersten M; Kerr B; Hendricks A; Boczany B; Rosenberg M; Jung D; Spector SA; Bryson Y
    Clin Infect Dis; 1999 May; 28(5):1109-18. PubMed ID: 10452644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
    King MS; Bernstein BM; Walmsley SL; Sherer R; Feinberg J; Sanne I; Cernohous P; Montaner JS; Brun SC; Sun E
    J Infect Dis; 2004 Jul; 190(2):280-4. PubMed ID: 15216462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies.
    Pérez-Alvarez L; Villahermosa ML; Cuevas MT; Delgado E; Manjón N; Vázquez de Parga E; Medrano L; Contreras G; Thomson MM; Colomo C; Taboada JA; Nájera R
    J Hum Virol; 2000; 3(3):150-6. PubMed ID: 10881995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
    Parkin NT; Lie YS; Hellmann N; Markowitz M; Bonhoeffer S; Ho DD; Petropoulos CJ
    J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nelfinavir, a new protease inhibitor: early clinical results.
    Powderly WG; Tebas P
    AIDS; 1999 Sep; 13 Suppl 1():S41-8. PubMed ID: 10546784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
    Masquelier B; Descamps D; Carrière I; Ferchal F; Collin G; Denayrolles M; Ruffault A; Chanzy B; Izopet J; Buffet-Janvresse C; Schmitt MP; Race E; Fleury HJ; Aboulker JP; Yeni P; Brun-Vézinet F
    Antivir Ther; 1999; 4(2):69-77. PubMed ID: 10682151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
    Lawrence J; Schapiro J; Winters M; Montoya J; Zolopa A; Pesano R; Efron B; Winslow D; Merigan TC
    J Infect Dis; 1999 Jun; 179(6):1356-64. PubMed ID: 10228055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral therapy in human immunodeficiency virus-infected individuals.
    Spooner KM
    Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.